Medeon Biodesign (6499) - Total Liabilities
Based on the latest financial reports, Medeon Biodesign (6499) has total liabilities worth NT$284.53 Million TWD (≈ $8.96 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Medeon Biodesign - Total Liabilities Trend (2017–2024)
This chart illustrates how Medeon Biodesign's total liabilities have evolved over time, based on quarterly financial data. See working capital to net assets of Medeon Biodesign to evaluate short-term liquidity relative to the company's equity base.
Medeon Biodesign Competitors by Total Liabilities
The table below lists competitors of Medeon Biodesign ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Paiho Shih Holdings Corp
TW:8404
|
Taiwan | NT$12.85 Billion |
|
Boyaa Interactive International Limited
F:1BY
|
Germany | €562.55 Million |
|
MFS Municipal Income Trust
NYSE:MFM
|
USA | $114.42 Million |
|
Exotic Food Public Company Limited
BK:XO
|
Thailand | ฿312.77 Million |
|
Bin Chuan Enterprise Co Ltd
TWO:1569
|
Taiwan | NT$3.53 Billion |
|
Shanghai Supezet Engineering Technology Corp Ltd
SHG:688121
|
China | CN¥5.71 Billion |
|
Cellectis SA
NASDAQ:CLLS
|
USA | $229.27 Million |
|
Laboratorio Reig Jofre S.A
MC:RJF
|
Spain | €138.18 Million |
Liability Composition Analysis (2017–2024)
This chart breaks down Medeon Biodesign's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Medeon Biodesign.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.03 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.26 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.20 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Medeon Biodesign's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Medeon Biodesign (2017–2024)
The table below shows the annual total liabilities of Medeon Biodesign from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$341.84 Million ≈ $10.77 Million |
-9.00% |
| 2023-12-31 | NT$375.65 Million ≈ $11.84 Million |
-0.22% |
| 2022-12-31 | NT$376.48 Million ≈ $11.86 Million |
+113.90% |
| 2021-12-31 | NT$176.00 Million ≈ $5.55 Million |
-73.61% |
| 2020-12-31 | NT$666.83 Million ≈ $21.01 Million |
+148.65% |
| 2019-12-31 | NT$268.18 Million ≈ $8.45 Million |
+80.12% |
| 2018-12-31 | NT$148.89 Million ≈ $4.69 Million |
+41.25% |
| 2017-12-31 | NT$105.41 Million ≈ $3.32 Million |
-- |
About Medeon Biodesign
Medeon Biodesign, Inc. engages in the research and development, manufacturing, and sale of medical devices in the United States. The company focuses on developing devices for minimally invasive surgeries, such as Cross-Seal, a large bore vascular closure system; Urocross, an expander system for treating lower urinary tract symptoms associated with benign prostatic hyperplasia; Duett, a vascular g… Read more